January 30, 2015 9:46 AM ET

Biotechnology

Company Overview of Tranzyme, Inc.

Company Overview

As of July 15, 2013, Tranzyme, Inc. was acquired by Ocera Therapeutics, Inc., in a reverse merger transaction. Tranzyme, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-based therapeutics primarily in the United States. The company’s pre-clinical product pipeline includes TZP-201, a motilin antagonist, for the treatment of various forms of moderate-to-severe diarrhea; and TZP-301, a ghrelin antagonist, for the treatment of metabolic diseases. The company has strategic collaboration with Bristol-Myers Squibb Company to discover, develop, and commercialize additional novel compounds. Tranzyme, Inc. was founded in 1998 and is headquar...

5001 South Miami Boulevard

Suite 300

Durham, NC 27703

United States

Founded in 1998

29 Employees

Phone:

919-474-0020

Fax:

919-474-0025

Key Executives for Tranzyme, Inc.

Tranzyme, Inc. does not have any Key Executives recorded.

Tranzyme, Inc. Key Developments

Tranzyme, Inc. Approves Amendments to the Certificate of Incorporation

at the special meeting of its stockholders approved amendments to certificate of incorporation to effect a reverse stock split of Tranzyme's common stock and related matters and approved an amendment to Tranzyme's certificate of incorporation to change the name of Tranzyme to Ocera Therapeutics, Inc.

Tranzyme, Inc.(NasdaqGM:TZYM) dropped from NASDAQ Composite Index

Tranzyme, Inc. will be removed from NASDAQ Composite Index.

Tranzyme Receives Non-Compliance Notice From NASDAQ

On July 2, 2013, Tranzyme, Inc. received a notice from the Nasdaq Stock Market (NASDAQ) stating that because the Company had not regained compliance with the $1.00 minimum bid price requirement for continued listing, as set forth in NASDAQ Listing Rule 5450(a)(1), the Company’s common stock, listed on The NASDAQ Global Market, would be subject to delisting on July 11, 2013 unless the Company requests a hearing before a NASDAQ Hearings Panel (the “Panel”) on or before July 9, 2013. The Company intends to request a hearing before the Panel. The Company believes that such a request will stay any delisting action until after the Company’s expected merger with Ocera Therapeutics, Inc. A special meeting of the Company’s stockholders to approve the Company’s merger with Ocera and other related matters is scheduled for July 15, 2013. The Company expects that NASDAQ’s decision with respect to the listing of the combined company’s common stock on The NASDAQ Global Market will be made around the time of the closing of the Company’s proposed merger with Ocera. The Company has been in active dialogue with NASDAQ regarding the above-described approach to the Notice as well as the initial listing application for the combined company’s shares following the merger with Ocera.

Similar Private Companies By Industry

Company Name Region
Prion Developmental Laboratories, Inc. United States
AbbVie Biotherapeutics Inc. United States
Recros Medica, Inc. United States
JR Scientific, Inc. United States
Axerion Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tranzyme, Inc., please visit www.tranzyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.